Saluda Medical's spinal cord stimulator effective in 36-month study

Spinal Tech

A long-term study of Saluda Medical's Evoke spinal cord stimulator found most patients had significant pain reduction and no explants, the devicemaker said Jan. 17.

The double-blind study evaluated 134 patients across 13 states over 36 months, according to a news release. Eighty-three percent of patients who recieved Evoke, a closed-loop system, saw a 50 percent or higher pain reduction at 36 months, and 59 percent saw 80 percent or higher pain reductions. Ninety percent said they were "satisfied" or "very satisfied" with Evoke.

The study also found there were no explants due to loss of efficacy after 36 months with Evoke.

The Evoke spinal cord stimulator is designed to address chronic pain in the trunk and/or limbs. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers